Dishman Carbogen Amcis Limited (NSE:DCAL)
India
· Delayed Price · Currency is INR 209.89
+3.59 (1.74%)
Mar 13, 2025, 3:29 PM IST
Dishman Carbogen Amcis Revenue
Dishman Carbogen Amcis had revenue of 6.82B INR in the quarter ending December 31, 2024, with 4.80% growth. This brings the company's revenue in the last twelve months to 26.50B, up 2.72% year-over-year. In the fiscal year ending March 31, 2024, Dishman Carbogen Amcis had annual revenue of 26.16B with 8.41% growth.
Revenue (ttm)
26.50B
Revenue Growth
+2.72%
P/S Ratio
1.24
Revenue / Employee
23.41M
Employees
1,132
Market Cap
32.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 26.16B | 2.03B | 8.41% |
| Mar 31, 2023 | 24.13B | 2.72B | 12.72% |
| Mar 31, 2022 | 21.41B | 2.29B | 11.96% |
| Mar 31, 2021 | 19.12B | -1.32B | -6.44% |
| Mar 31, 2020 | 20.44B | -150.00M | -0.73% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Zydus Lifesciences | 222.47B |
| Apollo Hospitals Enterprise | 211.46B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Dishman Carbogen Amcis News
- 27 days ago - Q3 2025 Dishman Carbogen Amcis Ltd Earnings Call Transcript - GuruFocus
- 2 months ago - Dishman Carbogen subsidiary successfully completes Swissmedic inspection of its Vionnaz facility - Business Upturn